MedTrace Logo

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

NCT01048983 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-03-05

No results posted yet for this study

Summary

The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Armodafinil

Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

DRUG

Bupropion

Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

DRUG

Minocycline

Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

DRUG

Curcumin

Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.

BEHAVIORAL

Telephone Questionnaire

Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Zhongxing Liao, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01048983 on ClinicalTrials.gov